Could non-pathogenic viruses provide an unrejectable therapeutic target?

Lessons learned in starting up a company – and navigating an industry dominated by men.

We sit down with Hanns-Christian Mahler, CEO of ten23 health.

Sitting Down With Dick Sundh, General Manager, Kite Pharma

Fungal infections and antifungal resistance are a significant problem; here’s one approach to consider

UK-based center will have capacity for RNA therapeutic production for clinical trials and potential future health emergencies.

We delve into the story behind Lonza’s collaboration with Asahi Kasei Bioprocess America.

Navigating the cell therapy partnership selection process can be complex. Here, I share the questions you should be asking to help you get it right.

How digitalization will revolutionize the way we develop and optimize bioprocesses.

The potential of the cell and gene therapies sector depends – partially – on the expertise of the transport and logistics partners that complement it.